


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

**VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE RECEIVES HKD39 MILLION MILESTONE
PAYMENT FROM MENARINI GROUP FOLLOWING FIRST-IN-HUMAN
ACHIEVEMENT FOR MEN2501**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, InSilico Medicine has received approximately HKD39 million from Menarini Group (“**Menarini**”) as an additional milestone payment, following the completion of first-in-patient dosing in a Phase I clinical trial of MEN2501.

About MEN2501 (ISM9682)

MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with potent activity in cancers with chromosome instability. As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, InSilico Medicine has licensed MEN2501 to Stemline Therapeutics, Inc., a wholly owned subsidiary of Menarini, with the combined value of the agreements exceeding USD550 million (equivalent to approximately HKD4.29 billion).

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, February 3, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.

For the purpose of this announcement, all figures in HKD are calculated based on the exchange rate of approximately USD1.00 to HKD7.80.